Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 419-426

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comments and reply on: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

By Currie Craig J.   McEwan Phil   Poole Chris   Valentine William J.   Palmer Andrew J.   Lammert Morten   Nicklasson Lars   Foos Volker   Roze Stéphane  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 967-969

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes

By Hompesch Marcus   Ocheltree Scott M.   Wondmagegnehu Eshetu T.   Morrow Linda A.   Kollmeier Alexa P.   Campaigne Barbara N.   Jacober Scott J.  

Current Medical Research and Opinion, Vol. 25, Iss. 11, 2009-11 ,pp. : 2679-2687

Informa Healthcare

Access to resources Recommend Favorite

Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir

By Peterson Gregory E.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2613-2619

Informa Healthcare

Access to resources Recommend Favorite

Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 554-559

John Wiley & Sons Inc

Access to resources Recommend Favorite